Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Nov 6 - Nov 11
Retatrutide is still being studied and is not fully approved yet, so long-term safety data are very limited
Semaglutide 2.4 mg (Wegovy) : A once-weekly injectable GLP-1 receptor agonist approved by the MHRA for chronic weight management
the clinical significance in humans remains under investigation and is not yet established for retatrutide specifically [24] [25] Other class-associated cautions: Based on the broader GLP-1/GIP receptor agonist class, potential effects on gallbladder function and delayed gastric emptying are relevant considerations, though evidence specific to retatrutide is still emerging It is important to note that this evidence derives from early-phase trials conducted under controlled conditions with medical supervision
Regular check-ins with your healthcare provider help avoid challenges and find fresh solutions as your body changes
US$ 23.04
US$ 22.38
US$ 24.13
US$ 20.17
US$ 25.33
US$ 27.79
US$ 23.67
US$ 27.08
